Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass. - Wikidata - wikimedia - TriplyDB

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.

http://www.wikidata.org/entity/Q36094013

about

Profile of romosozumab and its potential in the management of osteoporosis.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma New anabolic therapies for osteoporosis.The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.Pediatric Osteoporosis: Diagnosis and Treatment Considerations.New insights into the tonifying kidney-yin herbs and formulas for the treatment of osteoporosis.Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.A WNT protein therapeutic improves the bone-forming capacity of autografts from aged animals.MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.Emerging anabolic agents in the treatment of osteoporosis.Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.Application of anti-Sclerostin therapy in non-osteoporosis disease models.N-cadherin Regulation of Bone Growth and Homeostasis Is Osteolineage Stage-Specific.The challenges of diagnosing osteoporosis and the limitations of currently available tools.The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis.Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin.Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy Sialoglycoprotein from eggs improve high bone turnover activity via down-regulating BMP-2/Smads and Wnt/β-catenin signal pathways Treatment of Osteoporosis: Unmet Needs and Emerging Solutions

P2860

Q33596475-721A3C6E-A713-4957-A677-04CD3F58C083 Q33856318-53B1F9CB-F897-467F-A7B7-327AB97EBBFA Q38646406-88142DEF-59FF-40E5-85B3-E5E0DA1E21A8 Q38810794-16720E8B-53C1-4C52-8AD2-4BC411173D09 Q38921958-81D0057C-7991-4478-B86F-BDFFCB1B53E8 Q39106074-2A866ECE-22C7-4978-9D8D-6F2EAB101790 Q42364116-8DF1049D-2CB3-4C8C-A276-812046435AC4 Q47192623-22ED79F3-8A81-4FFC-90E1-5BAD1152E3E4 Q47428797-061C695B-32B0-4785-B05B-E8AD99E523D3 Q48012226-8D69F61F-0C20-4B59-9757-0CBF7194E93B Q48088703-B879630A-B412-440C-AE2E-E03D4B2B67C9 Q51363424-782A0858-5A12-46F9-94B9-40513397AB8D Q52786325-1549BA6C-4568-486F-A335-3400703A9AAA Q55113719-9A90D41D-5120-4680-A1F1-BBF2972F5488 Q55240717-9C877DA5-378D-428E-A62E-31A12CBF1A41 Q55517542-F50BB0DE-9275-464E-A069-81652D882642 Q57147876-22602BBF-2B74-4F5D-A0E5-89F85077C64F Q57497395-9B4A2D6C-3172-4D6F-9758-9C12800F3966 Q58780149-C9A36F34-DCA5-437B-BBA6-26DB38067CE6

P2860

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.

http://www.wikidata.org/entity/Q36094013

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Effects of Romosozumab Compare ...... usal Women With Low Bone Mass.

@ast

Effects of Romosozumab Compare ...... usal Women With Low Bone Mass.

@en

type

label

Effects of Romosozumab Compare ...... usal Women With Low Bone Mass.

@ast

Effects of Romosozumab Compare ...... usal Women With Low Bone Mass.

@en

prefLabel

Effects of Romosozumab Compare ...... usal Women With Low Bone Mass.

@ast

Effects of Romosozumab Compare ...... usal Women With Low Bone Mass.

@en

P1433

Q36094013-37DBBD83-448E-4165-8A13-7D7245F0C3C2

P1476

Q36094013-312FAACB-BF7E-4381-8F19-FF4D58E79967

P2093

Q36094013-0D254038-5686-4919-9963-C50E53B72557

Q36094013-2B18CDC9-8B09-4263-BF14-233B965870AF

Q36094013-3CC5FDB1-F9BC-4EC5-BF6D-CE57C6254D7A

Q36094013-509DF7A0-8008-411C-AD34-261495A81B6D

Q36094013-635E146A-3A5D-40ED-A153-E07DD3FA9A46

Q36094013-7CE5E60B-F1D3-4F39-8D89-DB4259A33F5A

Q36094013-90096078-EE77-46EE-ABC8-01C23885CC21

Q36094013-B3616007-5CF1-489F-A6DB-6FFB7EC6136C

Q36094013-BB6B720F-EC9F-4613-94A9-EA9B13D3BA28

Q36094013-ED9B8BC2-DEC9-40CF-9B79-83A23ECCBE1C

P2860

Q36094013-0445BD73-9F24-4789-BDA5-77267CE0BCF0

Q36094013-05BD6699-AD4F-4202-A288-375F70979929

Q36094013-09764D5A-BC92-4081-A7C4-6AA90EC07FD4

Q36094013-0D673DD2-A82B-4088-B73D-D019DD624228

Q36094013-35563934-DD7D-44C9-994E-41700A8644E7

Q36094013-4F31F2B7-9556-4507-B188-C06683DAE5E4

Q36094013-558521B4-D3E5-4AAB-B792-3F9F824C0B4D

Q36094013-6C02645C-D2DC-4F5A-A5E6-D263A6F52954

Q36094013-6F8B52A0-F461-4FBD-9A0D-28CC62B42969

Q36094013-704780E6-2734-4DC6-A817-12020A95AB0D

P304

Q36094013-0718E1CC-0CDF-458B-94EB-022A1721A1F2

P31

Q36094013-7DF3F20A-44DB-4E0F-A566-FFDAC4481A58

P356

Q36094013-63505B53-6485-4FA4-BB99-1AAAA44E6192

P433

Q36094013-C4619525-B6BD-4145-92AF-B32C56900ACB

P478

Q36094013-F513C96A-C965-4383-8E8C-8A76FD102D07

P577

Q36094013-709A9C31-B361-4AE1-B36E-21DE6C2DC8AF

P698

Q36094013-2665D0EB-F502-4998-A2F0-D07B4A828DD1

P356

P1433

Journal of Bone and Mineral Research

P1476

Effects of Romosozumab Compare ...... usal Women With Low Bone Mass.

@en

P2093

Andreas Grauer

http://www.w3.org/2001/XMLSchema#string

Carlos Mautalen

http://www.w3.org/2001/XMLSchema#string

Cesar Libanati

http://www.w3.org/2001/XMLSchema#string

Chris Recknor

http://www.w3.org/2001/XMLSchema#string

Harry K Genant

http://www.w3.org/2001/XMLSchema#string

Jacques P Brown

http://www.w3.org/2001/XMLSchema#string

Klaus Engelke

http://www.w3.org/2001/XMLSchema#string

Michael A Bolognese

http://www.w3.org/2001/XMLSchema#string

Stefan Goemaere

http://www.w3.org/2001/XMLSchema#string

Thomas Fuerst

http://www.w3.org/2001/XMLSchema#string

P2860

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Reanalysis precision of 3D quantitative computed tomography (QCT) of the spine.

Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study.

Advanced CT based in vivo methods for the assessment of bone density, structure, and strength.

Bone strength and its determinants.

A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.

Proximal femoral density distribution and structure in relation to age and hip fracture risk in women.

Microarchitecture, the key to bone quality.

P304

181-187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.2932

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27487526

http://www.w3.org/2001/XMLSchema#string